Skip to content

Ketamine: all studies

Page 374 of 449: studies 3,731 to 3,740 of 4,483, newest first. Back to the ketamine overview

Research

Psychoactive substances: novel molecular insights and therapeutic potential for Alzheimer's disease.

Translational neurodegeneration July 25, 2025 Chonglei Fu, Xuehui Li, Xiaoxing Liu et al. 2 citations

Alzheimer's disease (AD) is a major neurodegenerative disorder that causes severe cognitive decline and poses a significant burden on global health systems. Despite extensive research, effective treatments to stop neurodegeneration or promote neuronal regeneration in AD remain elusive. Psychoactive substances as modulators of neurophysiological functions, have received increased attention in...

DOI: 10.1186/s40035-025-00498-1 (opens in new tab) Full text (opens in new tab) Alzheimer's disease Challenges Molecular insights Psychoactive substances +6

Psychedelic use in individuals living with eating disorders or disordered eating: findings from the international MED-FED survey.

Journal of Eating Disorders July 24, 2025 Sarah-Catherine Rodan, Noah Meez, Sophie Lloyd-Hurwitz et al. 2 citations

There are few effective treatments for eating disorders (EDs), and new interventions are urgently needed. The MEDication and other drugs For Eating Disorders ("MED-FED") survey investigated the lived experience of adults with EDs regarding their prescription and non-prescription drugs use. Psychedelic drugs were highly rated in this survey for their impact on ED symptoms and general mental...

Bipolar disorder.

The Lancet July 22, 2025 Balwinder Singh, Holly A Swartz, Alfredo B. Cuellar Barboza et al. 66 citations

The hallmark of bipolar disorder is hypomania or mania, and the predominant phase of illness is depression. Affecting approximately 40 million individuals worldwide, bipolar disorder is associated with a substantial psychosocial, medical, and financial burden and increased mortality from suicide and other causes. Diagnosis can be challenging due to symptom overlap with attention-deficit...

DOI: 10.1016/S0140-6736(25)01140-7 (opens in new tab) Full text (opens in new tab) Bipolar disorder Mental health treatment Disease etiology Diagnostic challenges

Dynamical independence reveals anaesthetic specific fragmentation of emergent structure in neural dynamics

bioRxiv Preprint Server July 16, 2025 Borjan Milinkovic, Anil K. Seth, Lionel Barnett et al. 2 citations preprint

Conscious experience depends on the coordinated activity of neural processes that span multiple scales—from synapses to whole-brain dynamics. A recently introduced measure, dynamical independence, identifies, characterises and quantifies these multi-scale relationships using an information-theoretic dimensionality-reduction approach. Here, we use DI to examine changes in emergent dynamical...

Meditation and psychedelics facilitate similar types of mystical, psychological, and philosophical-existential insights predictive of wellbeing: a qualitative-quantitative approach.

Consciousness and Cognition July 7, 2025 Jussi Jylkkä, Hilla Väyrynen, Enyu Lin et al. 3 citations

Both psychedelic substances and meditation have been proposed to facilitate personally meaningful and transformative experiences, with insights playing a central role. However, previous research has mainly relied on questionnaires, limiting the range of insights that can be identified. In this study, we recruited participants who provided narrative reports of insights in personally meaningful...

DOI: 10.1016/j.concog.2025.103901 (opens in new tab) Profound personal insights Transformative insights Deep insights Mystical revelations +8

Prescription and Nonprescription Drug Use Among People With Eating Disorders.

JAMA Network Open July 1, 2025 Sarah-Catherine Rodan, Sarah Maguire, Noah Meez et al. 5 citations

There are few effective pharmacotherapies for treating eating disorders (EDs). High rates of substance use among individuals with EDs suggest potential self-medication of symptoms. To explore the experiences of individuals with EDs regarding use of prescribed and nonprescribed drugs. This survey study assessed responses to the Medications and Other Drugs for Eating Disorders (MED-FED) survey,...

Psychedelic-Assisted Therapy: Potential Benefits and Challenges in Mental Health Treatment

Medical Science Monitor June 30, 2025 Andrzej Silczuk, Robert Madejek, Tytus Koweszko et al. 4 citations

Psychedelics, derived from the Greek words "psyche" (soul) and "deloun" (revealing), are substances historically and currently considered "soul-revealing". Also termed hallucinogens due to their impact on sensory perception, they are further categorized into hallucinogens, such as lysergic acid diethylamide (LSD), psilocybin, and mescaline; entactogens or empathogens, such as...

DOI: 10.12659/msm.948302 (opens in new tab) Mental health Medline Psychotherapist Intensive care medicine

Exploring the integration of psychedelic-assisted therapy and digital mental health interventions in trauma recovery for underserved adults with high-functioning autism

Magna Scientia Advanced Research and Reviews June 28, 2025 Paul Okugo Imoh, Aderonke Ajiboye, Tahir Kolawole Balogun et al. 5 citations

Trauma-related disorders and substance use are disproportionately underdiagnosed and undertreated in individuals with High-Functioning Autism (Level 1 Autism Spectrum Disorder), particularly those in underserved or marginalized communities. Emerging evidence suggests that psychedelic-assisted therapies—including psilocybin, MDMA, and ketamine—offer promising outcomes in the treatment of...

DOI: 10.30574/msarr.2025.14.1.0079 (opens in new tab) Full text (opens in new tab) Psychological intervention Mental health Autism Clinical psychology +1

Use of Psychedelic Agents in Older Adults with Treatment-Resistant Major Depressive Disorder: What the Evidence Shows.

Drugs Aging June 24, 2025 Lou Vinarcsik, Charles Smoller, George Grossberg 1 citation

The use of drugs with psychedelic and dissociative effects for the treatment of psychiatric illnesses has become increasingly popular in recent years. However, few trials have been conducted to determine the efficacy of these agents in the specific setting of treatment-resistant major depressive disorder (MDD) in older adults. In this paper, we review notable aspects of treatment-resistant MDD...

DOI: 10.1007/s40266-025-01221-5 (opens in new tab) Innovative approach New avenue Agents Treatment +11

Beyond surgery: Repurposing anesthetics for treatment of central nervous system disorders.

Progress in Neuro-Psychopharmacology and Biological Psychiatry June 20, 2025 Joana Mielko, Julia Pakulska, Amelia Oszczyk et al.

The development of new drugs is a complex, expensive, and time-consuming process, often fraught with a high likelihood of failure. Amid these obstacles, drug repurposing, which identifies new therapeutic applications for already existing medications, offers a more economical and time-saving approach, particularly in the challenging field of neurological and psychiatric disorders. This narrative...

DOI: 10.1016/j.pnpbp.2025.111386 (opens in new tab) Full text (opens in new tab) Drug repurposing Neurological disorders Neuropsychiatric disorders Anesthetics anaesthetics +5